Assessing the correlation between SNP rs1800795 genotypes to serum Interleukin- 6 levels among COVID-19 patients in Iraq
DOI:
https://doi.org/10.51248/.v43i5.3259Keywords:
COVID-19, interleukin-6, SNP rs1800795, cytokines, gene polymorphismAbstract
Introduction and Aim: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces very high-inflammatory responses which is a major cause of COVID-19 disease severity and death. Interleukin-6 (IL-6), among other patient proinflammatory cytokines, especially its genomic polymorphisms that affect the body's immune system, can influence the course of infectious diseases. The aim of this study was to evaluate the relationship between IL-6 and COVID-19 disease in Iraqi patients.
Materials and Methods: This study included a total of 100 Covid-19 infected patients (50 with moderate and 50 with severe infection), and 50 healthy individuals (controls) from Iraq. DNA isolated from blood samples of each participant was subjected to PCR amplification of the SNP rs1800795 fragment of the Interleukin- 6 gene, which was further genotyped for the -174 G/C polymorphism. Serum interleukin- 6 (IL-6) levels were evaluated to assess the correlation between the IL-6 levels and the SNP rs1800795 genotypes.
Results: The levels of IL-6 in sera of moderate and critical COVID-19 groups were significantly higher and increased with intensity of COVID-19 disease. Hardy-Weinberg equilibrium analysis showed the SNP rs1800795 genotypes (GG, GC, and CC) to remain constant in COVID-19 patients and controls. The study also showed no significant differences (p>0.05) for the IL-6 serum levels in association to the three genotypes.
Conclusion: SNP rs1800795 genotypes do not pose a risk factor for developing severe COVID-19 in the Iraqi population. Increased age, on the other hand, could be considered a risk factor for COVID-19 outcomes. COVID-19 vaccination is highly efficient in preventing severe COVID-19 infection.
References
Rabaan, A.A., Al-Ahmed, S.H., Garout, M.A., Al-Qaaneh, A.M., Sule, A.A., Tirupathi, R., et al., Diverse immunological factors influencing pathogenesis in patients with COVID-19: a review on viral dissemination, immunotherapeutic options to counter cytokine storm and inflammatory responses. Pathogens, 2021;10(5):565.
Tahaghoghi-Hajghorbani, S., Zafari, P., Masoumi, E., Rajabinejad, M., Jafari-Shakib, R., Hasani, B., et al., The role of dysregulated immune responses in COVID-19 pathogenesis. Virus Research. 2020;290:198197.
Rowaiye, A.B., Okpalefe, O.A., Adejoke, O.O., Ogidiga, J.O., Oladipo, O.H., Ogu, A.C., et al., Attenuating the effects of novel COVID-19 (SARS-CoV-2) infection-induced cytokine storm and the implications. J Inflamm Res. 2021;14:1487.
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet.2020;395(10224):565-574.
Okabayashi, T., Kariwa ,H., Yokota, S.i., Iki, S., Indoh, T., Yokosawa, N., et al., Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. Journal of Medical Virology. 2006;78(4):417-424.
Wang, F., Nie, J., Wang, H., Zhao, Q., Xiong, Y., Deng, L., et al., Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. The Journal of Infectious Diseases. 2020;221(11):1762-1769.
Abbas, M.S., Ahmed, A.G., Ali, S.Q., AL-Rubaii, B.A.L. Immunological inflammatory factors in patients diagnosed with COVID-19. Biomedicine .2023; 43(1):230-235.
Heinrich, P.C., Castell, J.V., Andus, T. Interleukin-6 and the acute phase response. Biochemical Journal. 1990;265(3):621.
Kumar, H., Kawai, T., Akira, S. Pathogen recognition by the innate immune system. International Reviews of Immunology. 2011;30(1):16-34.
Channappanavar, R., Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in immunopathology: Springer; 2017;39:529-539.
Han, H., Ma, Q., Li, C., Liu, R., Zhao, L., Wang, W., et al., Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerging Microbes and Infections. 2020;9(1):1123-1130.
Santa Cruz, A., Mendes-Frias, A., Oliveira, A.I., Dias, L., Matos, A.R., Carvalho, A., et al., Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia. Frontiers in Immunology. 2021;12: 613422.
Yin, J.X., Agbana, Y.L., Sun, Z.S., Fei, S.W., Zhao, H.Q., Zhou, X.N., et al., Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis. Infectious Diseases of Poverty. 2023;12(1):1-14.
Gadient, R.A., Patterson, P.H. Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells.1999;17(3):127-137.
Giannitrapani, L., Augello, G., Mirarchi, L., Amodeo, S., Veronese, N., Sasso, B.L., et al., Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population. Journal of Infection. 2022;85(2):174-211.
Ghazy, A.A. Influence of IL-6 rs1800795 and IL-8 rs2227306 polymorphisms on COVID-19 outcome. The Journal of Infection in Developing Countries. 2023;17(3):327-334.
Verma, S., Verma, S., Khan, F.H., Siddiqi, Z., Raza, S.T., Abbas, M., et al., Genetic polymorphisms of IL6 gene–174G> C and–597G> A are associated with the risk of COVID-19 severity. International Journal of Immunogenetics. 2023;50(1): 5-11.
Apriningsih, H., Pratiwi, D., Nurinasari ,H. Association between IL-6 rs1800795 and IL-1beta rs 16944 gene polymorphisms with clinical severity of COVID-19 patients in Surakarta, Central Java, Indonesia. Bali Medical Journal. 2023;12(1):904-908.
Kerget, F., Kerget, B. Frequency of interleukin-6 rs1800795 (-174G/C) and rs1800797 (-597G/A) polymorphisms in COVID-19 patients in Turkey who develop macrophage activation syndrome. Jpn J Infect Dis. 2021;74(6):543-548.
Tarafder ,S., Khan ,N.M. Association of SARS-COV-2 viral RNAemia, IL-6 gene polymorphism, serum IL-6 and peripheral blood lymphocytes and monocytes with disease severity in COVID-19 patients. Clinical Immunology. 2023; 250:109605.
Smieszek, S.P., Przychodzen, B.P., Polymeropoulos, V.M., Polymeropoulos, C.M., Polymeropoulos, M.H. Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients’. Cytokine. 2021;148:155662.
Dhabaan, A.AN., Hamad, A.K., Hassoon, A.H. Association Between Covid-19 risk and the genotypes (Gg, Gc and Cc) And Its G and C Alleles for Interleukin-6 (Il-6) Gene Polymorphisms. HIV Nursing. 2022;22(2):567-570.
Rodrigues, FB.B., da Silva, R., Santos, EF.d., de Brito, MT.FM., da Silva, AL.S., de Meira Leite, M., et al., Association of polymorphisms of IL-6 pathway genes (IL6, IL6R and IL6ST) with COVID-19 severity in an Amazonian population. Viruses. 2023;15(5):1197.
Chen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., et al., Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clinical Infectious Diseases. 2020;71(8):1937-1942.
Tuncbilek, S. Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection. World Journal of Gastroenterology: WJG. 2014;20(20):6226.
Ansari ,M.A., Pedergnana, V., LC Ip, C., Magri, A., Von Delft, A., Bonsall, D., et al., Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nature Genetics. 2017;49(5):666-673.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Biomedicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Plum Analytics
